Sarepta, Nationwide Children's Hospital deal

The hospital granted Sarepta exclusive, worldwide rights to a preclinical gene therapy program that delivers the beta-1,4-N-acetyl-galactosaminyltransferase 2 (GALGT2; B4GALNT2) gene, which expresses a protein that performs a function similar to dystrophin. Sarepta hopes to begin a clinical trial of the therapy this year to treat Duchenne muscular dystrophy (DMD)...